タナカ ノリナ   Tanaka Norina
  田中 紀奈
   所属   医学部 医学科(東京女子医科大学病院)
   職種   助教
論文種別 原著
言語種別 英語
査読の有無 査読あり
表題 The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma.
掲載誌名 正式名:Experimental hematology
略  称:Exp Hematol
ISSNコード:18732399/0301472X
掲載区分国外
巻・号・頁 pp.in press
著者・共著者 Kinoshita Ryosuke†, Ishibashi Mariko, Handa Hiroshi, Sasaki Makoto, Imai Yoichi, Tanaka Norina, Ito Shigeki, Sunakawa-Kii Mika, Kaito Yuta, Asayama Toshio, Komatsu Norio, Tanaka Junji, Odajima Takeshi, Sugimori Hiroki, Yamaguchi Hiroki, Inokuchi Koiti, Tamura Hideto
発行年月 2023/02
概要 We previously showed that cell-surface CD86 expressed on multiple myeloma (MM) cells contributed to not only tumor growth but also antitumor cytotoxic T-lymphocyte responses mediated by induction of IL-10-producing CD4+ T cells. The soluble form of CD86 (sCD86) was also detected in serum from patients with MM. Thus, to determine whether sCD86 levels are a useful prognostic factor, we investigated the association of serum sCD86 levels with disease progression and prognosis in 103 newly diagnosed patients with MM. Serum sCD86 was detected in 71% of the patients with MM but was only rarely detected in patients with monoclonal gammopathy of undetermined significance and healthy controls, and the level was significantly increased in patients with advanced-stage MM. When we examined differences in clinical characteristics according to the level of serum sCD86, those in the high (≥2.18 ng/mL, n = 38) group exhibited more aggressive clinical characteristics, with shorter overall survival times compared with those in the low (<2.18 ng/mL, n = 65) group. On the other hand, it was difficult to stratify the patients with MM into different risk groups based on the expression levels of cell-surface CD86. The levels of serum sCD86 were significantly correlated with the expression levels of the messenger RNA (mRNA) transcripts of CD86 variant 3, which lack exon 6, resulting in a truncated transmembrane region, and its variant transcripts were upregulated in the high group. Thus, our findings suggest that sCD86 can be easily measured in peripheral blood samples and is a useful prognostic marker in patients with MM.
DOI 10.1016/j.exphem.2023.01.006
PMID 36796620